Design of 1-arylsulfamido-2-alkylpiperazine derivatives as secreted PLA2 inhibitors.

PubWeight™: 0.78‹?›

🔗 View Article (PMID 20571844)

Published in J Mol Model on June 23, 2010

Authors

Preethi Badrinarayan1, P Srivani, G Narahari Sastry

Author Affiliations

1: Molecular Modeling Group, Organic Chemical Sciences, Indian Institute of Chemical Technology, Tarnaka, Hyderabad 500 007, India.

Articles cited by this

CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res (1994) 392.47

Development and validation of a genetic algorithm for flexible docking. J Mol Biol (1997) 14.36

A fast flexible docking method using an incremental construction algorithm. J Mol Biol (1996) 7.33

Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc (1988) 6.41

Diversity of group types, regulation, and function of phospholipase A2. J Biol Chem (1994) 4.35

Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem (1994) 3.60

Amino acid sequence of phospholipase A2-alpha from the venom of Crotalus adamanteus. A new classification of phospholipases A2 based upon structural determinants. J Biol Chem (1977) 1.81

Increasing molecular diversity of secreted phospholipases A(2) and their receptors and binding proteins. Biochim Biophys Acta (2000) 1.76

Virtual screening in drug discovery -- a computational perspective. Curr Protein Pept Sci (2007) 1.32

Phospholipase A2 inhibitors as potential anti-inflammatory agents. Curr Pharm Des (2005) 1.18

Increased group II phospholipase A2 in colonic mucosa of patients with Crohn's disease and ulcerative colitis. Gut (1994) 1.11

Molecular lipophilicity potential, a tool in 3D QSAR: method and applications. J Comput Aided Mol Des (1994) 1.01

Crystal structure of the 1:2:2 adduct of piperazine, o-phthalic acid and water. Anal Sci (2003) 0.99

Indole inhibitors of human nonpancreatic secretory phospholipase A2. 3. Indole-3-glyoxamides. J Med Chem (1996) 0.97

In silico-guided target identification of a scaffold-focused library: 1,3,5-triazepan-2,6-diones as novel phospholipase A2 inhibitors. J Med Chem (2006) 0.92

Indole inhibitors of human nonpancreatic secretory phospholipase A2. 1. Indole-3-acetamides. J Med Chem (1996) 0.90

Characterization and activity of phospholipase A2 in normal human epidermis and in lesion-free epidermis of patients with psoriasis or eczema. Br J Dermatol (1985) 0.87

Indole inhibitors of human nonpancreatic secretory phospholipase A2. 2. Indole-3-acetamides with additional functionality. J Med Chem (1996) 0.85

Potential choline kinase inhibitors: a molecular modeling study of bis-quinolinium compounds. J Mol Graph Model (2008) 0.83

Molecular modeling studies of phenoxypyrimidinyl imidazoles as p38 kinase inhibitors using QSAR and docking. Eur J Med Chem (2007) 0.83

Molecular modeling studies of pyridopurinone derivatives--potential phosphodiesterase 5 inhibitors. J Mol Graph Model (2007) 0.83

Non-steroidal anti-inflammatory drugs as potent inhibitors of phospholipase A2: structure of the complex of phospholipase A2 with niflumic acid at 2.5 Angstroms resolution. Acta Crystallogr D Biol Crystallogr (2005) 0.81

Inhibition of secretory phospholipase A2. 2-Synthesis and structure-activity relationship studies of 4,5-dihydro-3-(4-tetradecyloxybenzyl)-1,2,4-4H-oxadiazol-5-one (PMS1062) derivatives specific for group II enzyme. Bioorg Med Chem (2005) 0.80

Secretory group II phospholipase A(2) : a newly recognized acute-phase reactant with a role in atherogenesis. Circ Res (2000) 0.76

A molecular modeling and 3D QSAR study of a large series of indole inhibitors of human non-pancreatic secretory phospholipase A2. Eur J Med Chem (2001) 0.76

Strategies to design pyrazolyl urea derivatives for p38 kinase inhibition: a molecular modeling study. J Comput Aided Mol Des (2007) 0.75

Structure-activity relationships in platelet-activating factor (PAF). 11-From PAF-antagonism to phospholipase A(2) inhibition: syntheses and structure-activity relationships in 1-arylsulfamido-2-alkylpiperazines. Eur J Med Chem (2001) 0.75